Dr. Tawfiq Al-Lahham is a neurologist with a subspeciality in neuromuscular medicine. We discuss with Dr. Al-Lahham how expanding multidisciplinary care is helping to make ALS a livable disease for everyone, everywhere until a cure is found.
The possibility of a government shutdown could have far-reaching and disastrous consequences for people living with ALS and those who depend on government-funded programs and support systems. A shutdown will disrupt the vital services and resources that many individuals with ALS and their families rely on daily.
With the Food and Drug Administration’s approval of the first gene-targeted therapy for ALS – and at least nine more in clinical development – genetic counseling and testing has become increasingly important. However, genetic counseling and testing is still not routinely offered to people with ALS in the United States.
This week is Malnutrition Awareness Week, an opportunity to remind everyone of the role proper nutrition plays in a person’s health and the importance of early detection, intervention and treatment of malnutrition for people living with ALS and their caregivers.
Gerald McCormick, a Gulf War veteran and former state legislator, used his connections and experience to join The ALS Association team of advocates and share his story.
Dr. Agessandro Abrahao, a professor of neurology at the University of Toronto and a neurologist at Sunnybrook Health Sciences Center, spoke about a new partnership between The ALS Association and the Focus Ultrasound Foundation and his work as a focused ultrasound investigator at the Harquail Centre for Neuromodulation.
We talked with including Dr. Kevin Rhine, a postdoctoral scholar at the University California San Diego, to learn more about his research, as well as his interests outside the lab.
There can be no doubt this time of year means “back to school” to so many families around the country. As students return back to campus, this year, we wanted to take the opportunity to introduce you to some of this year’s recipients of the 2023 Jane Calmes Scholarship Fund.
The ALS Association sent formal responses to Blue Cross Blue Shield of Illinois, New Mexico, Texas, Oklahoma, and Montana challenging their draft policies regarding coverage of Qalsody, approved by the FDA earlier this year for treatment of people living with ALS caused by the SOD1 gene mutation.